Skip to main content

Table 1 Baseline characteristics of the patient population

From: Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

 Patient population
n = 64 (100%)
Gender
 Male33 (51.6)
 Female31 (48.4)
Age
 < 60 years28 (43.8)
 ≥ 60 years36 (56.2)
GNAQ
 Mutated8 (12.5)
 Wildtype8 (12.5)
 Unknown48 (75.0)
GNA11
 Mutated10 (15.6)
 Wildtype5 (7.8)
 Unknown49 (76.6)
ECOG status
 049 (76.6)
 111 (17.2)
 21 (1.6)
 31 (1.6)
 Unknown2 (3.1)
Serum LDH
 Normal28 (43.8)
 Elevated (>ULN)33 (51.6)
 Unknown3 (4.7)
Previous systemic therapies
 050 (78.1)
 112 (18.8)
 ≥ 22 (3.1)
 Previous ipilimumab monotherapy2 (3.1)
 Previous PD-1 inhibitor monotherapy12 (18.8)
Liver-directed therapies
 033 (51.6)
 130 (46.9)
  ≥ 21 (1.6)
Metastatic sitesa
 Liver58 (90.6)
 Lung23 (35.9)
 Bone17 (26.6)
 Lymph nodes12 (18.8)
 CNS4 (6.3)
Treatment regimen
 Ipilimumab 3 mg/kg + nivolumab 1 mg/kg Q3W, followed by nivolumab 3 mg/kg Q2W59 (92.2%)
 Ipilimumab 1 mg/kg + pembrolizumab 2 mg/kg Q3W, followed by pembrolizumab 2 mg/kg Q3W5 (7.8%)
  1. aMultiple metastatic sites per patient were possible (values do not sum up to 100%); abbreviations: CNS Central nervous system, Q2W Every two weeks, Q3W Every three weeks